Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edding Genor Group Holdings's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.43.
Edding Genor Group Holdings does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025.
During the past 12 months, the average EBIT per Share Growth Rate of Edding Genor Group Holdings was 18.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Edding Genor Group Holdings's EBIT per Share or its related term are showing as below:
HKSE:06998's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.8 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Edding Genor Group Holdings (HKSE:06998) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Edding Genor Group Holdings EBIT per Share Related Terms
Edding Genor Group Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings (HKSE:06998) has a EBIT per Share of HK$ as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Edding Genor Group Holdings and its competitors. According to the industry distribution chart, Edding Genor Group Holdings ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is Edding Genor Group Holdings' EBIT per Share too high?
Edding Genor Group Holdings' current EBIT per Share is HK$. Based on the distribution chart, Edding Genor Group Holdings ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #999999 out of 809 companies for EBIT per Share. This places Edding Genor Group Holdings in the lower half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current EBIT per Share is HK$. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current EBIT per Share of HK$. The current EBIT per Share is HK$. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current EBIT per Share is HK$ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
